healiva® is a Bioseutica backed innovative Swiss startup venture located in Lugano. It develops products for regenerative medicine.
healiva® uses a multi-pronged approach combining digital health, enzyme technology and cell therapy to address patient needs for repairing, rescuing or replacing damaged cells or tissues in their body.
healiva® has core interests in innovating in cell therapy, enzyme technology, data analytics and medical devices to bring to the market products by accelerating the translation from bench-to-bedside. To provide patients and healthcare professionals with advanced products and therapies for regenerative medicine by leveraging on best in class innovations.
We aim to develop, supply and assist patients with innovative cell therapies and products for regenerative medicine, also in association with enzymes, natural or synthetic molecules. We are patient centric cell therapy company, delivering personalised and precision medicine by leveraging on best in class innovations.
December 14 2020 | Lugano
healiva® is proud to announce to be the first start-up to join the Farma Industria Ticino Association as official member. Healiva is open to collaborate with an external innovation team of biotechs, pharmaceuticals to bring in personalized therapeutics solutions to market at an accelerated speed.Read More FIT website FIT members
November 18 2020 | Basel
November 18-19 2020 | Virtual
July 19-20, 2021 | Paris
Owing to the Swiss Italian heritage influence as a start-up we take the concept of regenerative medicine as coined William Haseltine during a 1999 conference on Lake Como a few minutes drive from our office. We aim to provide solutions and treatments for various chronic diseases by converging and combining emerging tools and cutting edge technologies from tissue engineering, cell transplantation, stem cell biology, biomechanics, biochemistry and immunology areas.
With our medical grade naturally occurring enzymes produced with proprietary technologies by our partner Bioseutica BV, we provide patients and healthcare practitioners with efficient alternative solutions to chemical or surgical interventions.
Our pipeline includes a scalable, automated solution towards cell therapy with a focus on chronic conditions, primarily resulting from metabolic diseases. We aim to provide patients and healthcare practitioners with efficient tools and precision solutions for tissue repair, replacement or regeneration.
Our vision of bespoke solutions towards treating unmet medical needs, we leverage various emerging and existing solutions in digital healthcare domain, like continuous real-time data streaming and biosensor device solution powered with digital tools to enable better response rate and lower failures rates for cell based therapies.
Priyanka has a Ph.D. in Neuroscience from Trinity College Dublin, Ireland and an executive MBA from WU Executive Academy, Vienna, Austria and Carlson Business School, University of Minnesota, USA. Currently, she is working as Corporate Sales and Business Development Director at Bioseutica Group in pharmaceutical, food and feed industry. She is also Co-Founder and Board Member of WU EA Female Leaders Network in Austria.
Priyanka has 10+ years of experience in leading roles in the pharmaceutical and biotechnology industry including Novartis AG, Switzerland, UCB Pharma, Belgium and Axol Bioscience, UK.
Paolo Magrì is CEO of the Bioseutica Group, active in the production of pharma grade natural proteins and enzymes. The Group is headquartered in The Netherlands, with offices in Switzerland and production sites in British Columbia (CA).
Mr. Magrì has over 30 years of experience in the active pharmaceutical ingredient (API) industry, and he is currently on the Board of DCAT, where he served as President of the Association for two terms, from 2018 until 2020.
Prior to joining Bioseutica, he was senior VP at Advitech Advisory and Technologies. Previous to that role, he worked at INFA Group as Vice President of corporate business development, and as marketing and sales Director at Sicor and in Teva’s API division, after the acquisition of Sicor by Teva in 2004.
His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras. Mr. Magrì earned his Master’s degree in chemistry and pharmaceutical technology from the University of Milan, Italy.
Jay is the Chief Innovation and Strategy officer of Healiva SA and has served as Chief Scientific Officer of Bioseutica BV previously. Jay has more than 10 yrs of industrial experience across both pharma and food sectors, in areas of drug development, innovation management, R&D strategy, business development and alliance management. Jay has been associated with Nestle and Novartis during his career and is passionate about microbiome, data analytics, open source software and teaching. Jay received his PhD from the university of Pune, India and MBA from EPFL, Switzerland.
Eric holds a Ph.D. in biochemistry from Claude Bernard University (Lyon, France) and an Industrial Biology Engineer degree from ‘Conservatoire National des Arts et Métiers’ (Lyon, France).
Eric has over 30 years of experience managing research in the biotechnology and pharmaceutical industries. Eris was most recently director of the Nestlé Institute of Health Sciences (Lausanne, Switzerland). Prior to joining Nestlé, Eric was the General Manager of the Swiss operations and the global VP of R&D at HealthPoint Biotherapeutics (Lausanne, Switzerland, Fort Worth, USA). He previously served as VP of R&D at IsoTis Orthobiologics (Lausanne, CH, Bilthoven, NL, Irvine, USA) and as Head of R&D at Modex Therapeutics (Lausanne, Switzerland). Prior to Modex, Eric held R&D management and scientific positions at Gambro (Meyzieu, France) and Mérieux (Lyon, France).
healiva® is a Bioseutica backed innovative Swiss startup venture located in Lugano combining digital health, enzyme technology and cell therapy to deliver personalised and precision solutions for regenerative biology.